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Abstract:  29 
Background: Clinical practice guidelines are widely used in primary care, yet are not always based on 30 
applicable research.  31 
Aim: To explore primary care practitioners’ views on the applicability to primary care patients of 32 
evidence underpinning National Institute for Health and Care Excellence (NICE) guideline 33 
recommendations. 34 
Design: Delphi survey and focus groups. 35 
Method: Delphi survey of the perceived applicability of 14 guideline recommendations rated before 36 
and after a description of their evidence base, followed by two focus groups. 37 
Results: General practitioners (GPs) significantly reduced scores for their perceived likelihood of 38 
pursuing recommendations after finding these were based on studies with low applicability to 39 
primary care, but maintained their scores for recommendations based on highly applicable research. 40 
GPs reported they were more likely to use guidelines where evidence was applicable to primary care, 41 
and less likely if the evidence base came from a secondary care population. Practitioners in the focus 42 
groups accepted that guideline developers would use the most relevant evidence available, but 43 
wanted clearer signposting of those recommendations particularly relevant for primary care patients. 44 
Their main need was for brief, clear, and accessible guidelines.  45 
Conclusion: Guidelines should specify the extent to which the research evidence underpinning each 46 
recommendation is applicable to primary care.  The relevance of guideline recommendations to 47 
primary care populations could be more explicitly considered at all three stages of guideline 48 
development: scoping and evidence synthesis, recommendation development, and publication. The 49 
relevant evidence base needs to be presented clearly and concisely and easy to identify way.   50 
 51 
How this fits in: 52 
Clinical practice guidelines are intended to improve the quality of patient care, but general 53 
practitioners do not always follow guidelines. The evidence base for most guidelines is derived from 54 
research conducted on secondary care populations in secondary care settings. This study shows that 55 
GPs regard the setting of evidence for guidelines as relevant to their use, and are more likely to use 56 
guideline recommendations where the evidence is applicable to their population. Clearer description 57 
of the applicability of research to primary care patients in a brief accessible guideline format may 58 
result in improved implementation in primary care, and help to maintain the currently high levels of 59 
trust in NICE guidance.  60 
61 
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Introduction 62 
Clinical practice guidelines are recommendations intended to improve the quality of patient care 63 
and should be based on a systematic review of the current relevant available evidence and an 64 
assessment of the benefits and harms of alternative care options (1). Guidelines are seen as one of 65 
the key foundations for quality improvement in England and internationally (2), but their impact on 66 
clinical practice has been variable (3, 4).  67 
GPs do not always follow guidelines (5-8), attributing their decisions to concerns about relevance 68 
and feasibility, and that strict exclusion criteria in clinical trials may reduce generalizability to the 69 
broader primary care patient population (9-12). Some guidelines have been found to have limited 70 
applicability to general practice settings (10, 11, 13, 14). Other identified barriers to guidelines 71 
adherence by primary care practitioners include lack of awareness, unfamiliarity, and disagreement 72 
with recommendations (13-16), and concern that the increasing use of guidelines as performance 73 
measures can distort patient centred clinical practice(17). General practitioners were more likely to 74 
follow evidence based guideline recommendations rather than those not based on research 75 
evidence, and wanted more transparency about the research base (9, 15, 18). However, barriers and 76 
consequent efforts to improve uptake of guidelines may be different in different settings (19) .  77 
The National Institute for Health and Care Excellence (NICE) is the chief national source of clinical 78 
guidance for England and Wales (20) . NICE makes considerable efforts to assist primary care 79 
practitioners to use relevant evidence for their patients, including web-based guidance for general 80 
practice and primary care professionals about keeping abreast of new NICE guidelines, and monthly 81 
summaries of guidelines which are particularly relevant for primary care. NICE provides different 82 
versions of their guidelines, with the full detailed guideline being clearly differentiated from briefer 83 
versions for clinicians, the public and commissioners. More recently, NICE has been responsible for 84 
managing the Quality and Outcomes Framework (QOF), a pay for performance scheme for British 85 
general practice which takes clinical guidelines as the starting point for the development of clinical 86 
indicators (21). 87 
We have previously reported that NICE guideline recommendations for primary care were not 88 
always based on research conducted on, or generalisable to, primary care populations (22, 23), and 89 
in this study we aimed to find out whether that mattered to primary care practitioners. We 90 
therefore aimed to explore primary care practitioners’ views of the applicability of primary care 91 
evidence in NICE guidelines. 92 
 93 
Methods  94 
There were two main stages, a  two-round online Delphi survey of general practitioners (GPs) to test 95 
the impact of additional information on practitioner views(24), followed by two focus groups with 96 
GPs and nurses, to explore the findings from the Delphi survey in more detail. 97 
Recruitment 98 
For the online Delphi we aimed to recruit 30 GPs nationally through adverts placed in the Society for 99 
Academic Primary Care (SAPC) and Royal College of General Practitioners (RCGP) newsletters, and 100 
regionally through the Primary Care Research Network in the East of England. This population was 101 
targeted for their likely interest and expertise in the study topic.  102 
For the two focus groups we aimed to recruit 8-10 participants for each focus group, and excluded 103 
those who had already responded to the Delphi. A total of 115 practices in Norfolk and Waveney 104 
were invited by the Primary Care Research Network (PCRN). Participants were purposively sampled 105 
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for their professional background and expertise (25, 26), and then all consenting respondents were 106 
utilised in the study. 107 
Online Delphi survey 108 
Delphi techniques allow experts to express individual views on complex material in a structured and 109 
systematic way, and test the extent of change of view (or not) as a consequence of additional 110 
feedback; this can be used to develop consensus but can also be used to test the stability and range 111 
of expert views(27). The survey was piloted on a small group of general practitioners. Two rounds of 112 
the final survey were administered online using SurveyMonkey (28) between November 2012-113 
January 2013. The survey (Appendix 1) included demographic questions including involvement with 114 
guidelines and then two main sections, first about the applicability of primary care evidence, and 115 
then about attributes that might affect guideline use.   116 
All recommendations used had been previously assessed as clinically relevant to primary care by at 117 
least two GP reviewers, as described elsewhere (23). First, participants were presented with the full 118 
text of 14 primary care relevant recommendations from NICE guidelines and asked to rate each 119 
recommendation on a scale of 1-9 for applicability to their primary care patients, with 1 being not 120 
likely to use with their patients) and 9 being highly likely to use. An electronic link to each full NICE 121 
guideline was given for reference. After participants had rated each recommendation, they were 122 
given a brief summary of the applicability to primary care of the supporting evidence, and then 123 
asked to rate the recommendation again. 124 
The recommendations were purposively selected to include a range of high, medium and low 125 
applicability of the evidence base to primary care patients. The applicability of evidence for each 126 
recommendation was rated as low if evidence for the recommendation was supported by no studies 127 
conducted on primary care or community populations, medium if supported by up to half of the 128 
studies, and high if the majority of the studies cited as evidence had their participants selected from 129 
primary care or the community, as described elsewhere (23).Recommendations were presented in 130 
the survey in a random order (Appendix 1). 131 
In the second component of the Delphi, participants were asked to rate on a scale of 1-5 (with 1 132 
being “strongly disagree that this attribute is most likely to encourage use of clinical guideline” and 5 133 
being “strongly agree”) a list of 16 attributes affecting guideline use, collated from the literature and 134 
arranged under four categories.  The participants were also asked to provide free text comments, 135 
which were analysed thematically. 136 
After the first round, each participant was sent the mean scores, as well as their own scores, and 137 
then asked to re-rate both the recommendations and the attributes in a second round. The 138 
difference in mean scores before and after reading the evidence summary was tested using a paired 139 
t-test, after tests for normality in Stata/SE (29).  140 
Focus groups 141 
Results from the Delphi panel were used to develop a focus group topic guide (SEE APPENDIX 2). 142 
Guideline attributes identified as important for the implementation and applicability of primary care 143 
recommendations, including the importance of primary care research, were explored with two focus 144 
groups, one with GPs and the other with primary care nurses. The focus groups were held separately 145 
to allow free expression of views, particularly from practice nurses who are usually employees of 146 
GPs, but the data from both groups were analysed together. 147 
The focus groups were conducted during January and February 2013 and were facilitated by an 148 
independent researcher to ensure impartiality, assisted by a member of the research team (AA). 149 
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They were taped and transcribed, and then analysed thematically using NVivo software (30) by two 150 
of the researchers (AA, AH) using the framework approach (31, 32).  151 
Results 152 
Online Delphi survey 153 
Twenty-eight GPs agreed to take part in the Delphi panel, of whom ten were recruited through 154 
national, and 18 through regional approaches. 25/28 (89%) completed the first round and 21/25 155 
completed the second round. The participants represented a broad range of experience in general 156 
practice, with most being service GPs (80%) with no experience of guideline development (88%) 157 
(Table1).  158 
Insert table 1 159 
Recommendation ratings for applicability to primary care patients  160 
Mean ratings for the recommendations’ applicability to primary care patients were lower after 161 
presentation of evidence for those recommendations where the summary disclosed that less than 162 
half of the studies were applicable to primary care populations. Mean ratings remained the same or 163 
increased for recommendations where the majority of cited publications were applicable to primary 164 
care populations (Table 2). While the majority of respondents altered their ratings modestly (raising 165 
or lowering by 1-2 points) after reading the evidence summary, few respondents didn’t change their 166 
initial ratings.  Ratings did not change substantially in the second round, and are not given here. 167 
Participants’ free text comments included that the wording of some recommendations was complex 168 
or not clearly defined, and that a GP ‘user’ perspective should be included at all stages of guideline 169 
development. Some were concerned about the UK applicability of the studies, and not just primary 170 
care applicability. Many respondents considered having some evidence is better than having no 171 
evidence, and others commented on the importance of clinical experience when implementing 172 
guidelines. 173 
“Overall it appears that I am less critical [than other respondents to the Delphi] of guidelines that do 174 
not originate specifically from primary care – but my reasons for this are ‘laissez-faire” rather than 175 
believing other sources are more important. Overall I considered whether the guideline was in 176 
keeping with what, for other reasons, I believe to be good practice, and/or whether it complies with 177 
the old adage “first, do no harm”. Most of the recommendations considered met these criteria (e.g. 178 
prescription of thiamine): if the guidelines were suggesting radical change to practice or invasive 179 
treatments I would be much less likely to give them credence without rigorous evidence.” GP (Delphi) 180 
Insert table 2 181 
Attributes affecting guideline use 182 
GPs rated nearly all 16 factors as likely to encourage guideline use, including ‘Study outcomes used 183 
are relevant and important to primary care population’ (Table 3). The notable exception was 184 
‘Evidence underpinning recommendation comes from secondary care population’, which was the 185 
only attribute with a mean score of less than 3/5. Attributes relating to guideline accessibility such as 186 
clarity, brevity and accessible format scored highly. Scores did not change in the second round. 187 
Insert table 3 188 
Focus groups 189 
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Ten GPs and ten primary care practice nurses agreed to take part, and six GPs (three men and three 190 
women) and ten nurses (all women) , all from different practices, attended. Four themes were 191 
identified: ’guideline use’, ‘evidence base’, ‘barriers to use’, and ‘pay for performance’. 192 
1. Guideline use 193 
Primary care practitioners in general and nurses in particular were positive about guidelines and 194 
used them where there was clinical uncertainty, often in short formats. 195 
Insert quotes 196 
2. Evidence base 197 
Primary care practitioners rarely looked at the evidence behind recommendations unless the 198 
recommendation seemed very different from their normal practice.  199 
Insert quotes 200 
Few had detailed understanding of guidelines formulation with regard to wording and how it’s used 201 
to reflect strength of evidence.  202 
Insert quotes 203 
Participants were aware of the need to interpret research findings for primary care and were 204 
pragmatic about this, and hopeful that future guidelines would have more primary care evidence 205 
and greater clarity about inevitable gaps in evidence. There was support for clearer labelling of 206 
primary care based evidence.  207 
Insert quotes 208 
Applicability of evidence 209 
Some participants argued that good evidence from secondary care could not be realistically 210 
implemented in a primary care population. 211 
Insert quotes 212 
3. Barriers to use 213 
Participants saw the number of guidelines, time available, and limits of evidence as constraints on 214 
their practical use and appraisal of guidelines. They highlighted that guidelines mostly addressed the 215 
management of specific conditions post-diagnosis, while primary care practitioners predominantly 216 
deal with comorbidities and symptoms pre-diagnosis. They wanted guidelines to be short and clear. 217 
Insert quotes 218 
4. Pay for performance 219 
The UK’s national primary care pay for performance scheme or ‘quality and outcomes framework’ 220 
(QoF) was identified as a key driver for compliance with guideline recommendations, though some 221 
concerns were expressed about the impacts of this on professional practice and the associated 222 
opportunity cost. Limited resources may impede on primary care practitioners’ ability to explore 223 
aspects of clinical care beyond QoF incentivised practice and this could be a hindrance to 224 
implementation of non- QoF guidelines.  225 
Insert quotes 226 
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 227 
Overall, NICE guidelines were viewed favourably as a major source of practice guidance.  Participants 228 
commented on the large numbers of guidelines, their need for concise summaries, the advantages 229 
of user-friendly web based versions, and the need to identify relevant guidelines quickly when 230 
uncertainty drove usage. The groups felt they had to trust the process of derivation and the 231 
comprehensive uploading of relevant guidelines, as they had little time to check either background 232 
or the availability of guidance. There was considerable evidence of individuals and practice teams 233 
trying to be systematic about updating local protocols and templates in line with new guidance, but 234 
with concern about the time and feasibility of this given the pressures of work and numbers of 235 
guidelines. Streamlining of local protocols across the team, between practices, and with secondary 236 
care, and the requirement to meet multiple guidelines as well as QoF indicators all presented 237 
additional challenges. 238 
 239 
Discussion 240 
Delphi participants considered that recommendations based on evidence from primary care 241 
populations were more applicable to their patients than those with no or little primary care evidence. 242 
Focus groups wanted clearer signposting of how applicable guideline evidence was for primary care, 243 
and expected significant involvement of primary care practitioners in scoping and developing 244 
guidelines. Primary care practitioners were constructively critical of the lack of evidence and lack of 245 
explicit declaration of this, and took a pragmatic view of implementing guidance. Brevity, clarity and 246 
accessibility were important guideline attributes.  247 
Strengths and limitations 248 
This study is the first systematic interrogation of primary care practitioner views on the applicability 249 
of primary care evidence in NICE guidelines for primary care. The study demonstrates that there are 250 
ways in which primary care practitioners perceive that these guidelines could be made more 251 
relevant and thus have more impact upon clinical practice. The participants were likely to be 252 
interested in guideline work or they would not have volunteered to take part in the study, and so the 253 
results of this study are likely to represent a relatively well informed and ‘guideline positive’ set of 254 
respondents. 255 
Comparison with existing literature and implications for research and practice  256 
Our findings about attributes that influence the use of guidelines in primary care agree with previous 257 
research, which highlighted clarity and clinical applicability of a guideline as important (9, 18, 33, 34). 258 
NICE recommends exploring and assessing the applicability to primary care patients under the 259 
“indirectness domain” of the modified GRADE criteria, “assessing the degree of differences between 260 
the population, intervention, comparator for the intervention and outcome of interest” (35). This 261 
exploration of generalisability to the target population is also described in the AGREE II tool criteria 262 
(36) which national clinical guideline developers are expected to use, and the NICE guidelines 263 
manual (37). Despite these intentions and efforts to make guideline evidence applicable to primary 264 
care, this study has shown that primary care practitioners would like clearer descriptions of the 265 
applicability of evidence to primary care patients. 266 
Other countries have used different approaches to developing guidelines for primary care, some of 267 
which may have potential benefit internationally. The New Zealand hand book for primary care 268 
compiles relevant recommendations from several guidelines (38) producing a type of “umbrella 269 
guideline” that has been recommended to NICE by the WHO review programme (39). The Dutch 270 
College of General Practitioners also produces national clinical guidelines that are dedicated to 271 
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primary care (40). These models have potential to improve the accessibility of relevant guidance for 272 
primary care. 273 
We suggest that primary care relevance should be more explicitly considered at all three main stages 274 
of guideline development: scope & evidence synthesis, recommendation development, and 275 
publication. This builds on the guidance NICE issues its guideline developers as part of their quality 276 
assurance process (37). At the stage of scoping the content of the guideline and evidence synthesis, 277 
primary care relevance should be considered from the outset of the initial scoping exercise and be 278 
clearly reported to the guideline development group. Ideally there would be input from primary care 279 
professionals with relevant content expertise and contextual understanding to interpret the existing 280 
evidence and its applicability to their patients. If the scope identified that the guideline had primary 281 
care relevance, then the initial review questions for the evidence search and the early findings 282 
should be specifically considered for applicability to primary care, with primary care routinely 283 
considered as a sub-group in the search. When an initial review question is relevant to primary care, 284 
the relevant population should be defined by primary care setting, severity of illness, or risk group in 285 
the search strategy and data extraction, and findings reported if evidence is not located.  286 
At the stage of recommendation development, any limitations or lack of evidence in relevant 287 
populations (e.g. defined by primary care setting, severity of illness, or risk group) should be 288 
specified in the summary of evidence tables. The ‘evidence to recommendations’ statement should 289 
be specific about where primary care research has or has not been reported, and recommendations 290 
where applicable primary care evidence was lacking should be clearly badged. Recommendations 291 
should be concise, with a clear pathway back from recommendations to research evidence, to allow 292 
users to “drill down” into the detail more easily. 293 
In the final published guideline, the target population should be clearly stated (e.g. defined by 294 
primary care setting, severity of illness, or risk group), and the relevance to that population of all 295 
recommendations and intended users clearly described. The published guideline should show which 296 
recommendations are supported by consensus, and which by research. It should specify the extent 297 
to which the research is applicable to specific populations including primary care, and openly 298 
acknowledging uncertainty where present in the guideline development group or the available 299 
evidence. All guidelines should be peer reviewed with respect to the clarity with which the relevance 300 
of recommendations to primary care is described. We acknowledge primary care evidence is often 301 
limited and that evidence from other settings should then be used but, if this is the case, this should 302 
be highlighted as a research recommendation in the final guideline. 303 
Primary care practitioners have a high level of trust for NICE guidelines, but were less likely to trust 304 
and want to use those recommendations with low applicability of evidence to primary care. Clearer 305 
description of the applicability of research to primary care patients, ideally within a brief accessible 306 
guideline format, may result in improved guideline implementation in primary care, and help to 307 
maintain the currently high levels of trust in NICE guidance.  308 
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Box 1: Focus group quotes 418 
 419 
 420 
Guideline use: 
“When you want to find something out or you’re unsure of something, you might go in retrospect and then look at the guidelines and 
see what you perhaps should have done but to learn from the guideline” (GP). 
“I actually no longer read what NICE has got to say about it, I go to one of those …digest websites which condenses it into one screen 
and I can read it off of there and if I detect anything that I would do differently, then I go back and I will expose myself to the whole 
guideline which is otherwise too hard work to read” (GP). 
“… just use the quick reference.  And we get email alerts with the new guidance that’s come out or been updated and we usually see if 
there’s anything relevant…..if there’s anything I need to use, I go and have a look at it then” (Nurse). 
Evidence base (a):“So where there is evidence, I’m sure they do a fab job and I don’t need to read the evidence myself to believe 
them” (GP). 
 “I’ve looked once at the … behind the guidance, I think it was for cardiovascular risk screening and I have to say I really wouldn’t look 
forward to doing it again because there were 382 pages to trawl through and it pulled every aspect of each screening tool to bits” (GP). 
“Well you might do, that’s a point … if it was something completely different, you might just want to look at the evidence base I think.  
If it was quite a different way of treating somebody I think I would have a look at the evidence base then” (Nurse). 
Evidence base (b): 
“I think as time goes on and more research is done in primary care that that evidence needs to contribute towards the guidelines so it’s 
not just secondary care” (Nurse). 
“I’ve been happy to rely on the NICE guidelines for the evidence that they’ve reviewed.  And I’m sure they did a great job of reviewing 
that with the best-available methods to rate evidence but what you can’t see is the gap, which bit is the bit that they just picked out of 
thin air because they have to cover that area because there is no evidence?  And if there is no evidence, then they can say whatever 
they think is necessary, which is no better than what I can say on the subject” (GP). 
Evidence base (c)“Certainly where you’re using NICE guidance, it would be nice to know that they’ve been done with the thought of 
general practice in mind” (GP). 
Applicability of evidence: 
“think if you’re doing it, again depending on the subject area, if you did look at all the evidence you’d not find much … it’s so skewed 
towards what’s being done in secondary and tertiary centres and not again what’s happening in the real world with GP patients and 
what’s … like say the number of patients that are not taking their Adacal, I mean how many people have probably done little audits on 
that?  But there’s probably not a research paper out there that NICE would be able to get their hands on to say ‘Well look, the evidence 
there’ but people don’t take … if they haven’t got the evidence, they can’t do …” GP 
“I was the only GP on that guideline.  And the problem that we’d got, we had with the guideline, was that NICE were brilliant at looking 
at all of the evidence but a lot of the evidence was from America, a lot of the evidence was from various European countries.  There 
was very, very little research from the UK and even less of any research from Primary Care populations.  So there was no evidence to 
base a Primary Care guideline on.  So we had to go with what was available and had to keep adapting.  But you were only there as the 
one GP trying to bring it back to the real world, well actually you know, what’s realistic and what sounds realistic and what they think is 
an ideal and what is actually realistic is very different”. GP  
   Barriers to use 
“I think there’s just too many for us to follow any more than just 1% if you like” (GP). 
“So you wouldn’t ever go to the guideline unless you’d had that diagnosis in your head” (GP). 
“I think the problem is if you’ve got somebody who’s got several comorbidities and you’re trying to do one but it doesn’t sit well with 
another one maybe” (Nurse). 
“And also keeping it to sort of one sheet of A4 format or a flow chart, a flow chart with a patient pathway” (GP). 
“I don’t think it’s dealt with by NICE particularly.  I don’t think it’s dealt with by NICE, comorbidity” Nurse  
Pay for performance 
“with the diabetes you know, the NICE recommendations on ACE inhibitors and statins and things like this, GPs have tended to go to do 
because they have their QOF box to tick that they’ve done these things” (GP). 
“I think to be fair, a lot of it’s targeted towards QOF when you’re writing a template” (Nurse). 
Table 1: Delphi survey participants’ characteristics 
Gender:  Male 12 (48%)  
                 Female 12 (48%)  
                 Prefer not to say 1 (4%)  
Years as a GP:   <5 yrs 5 (20%)
                             5-15 5 (20%) 
                             15-25 8 (32%)
                            25-35 7 (28%) 
Primary role:  Service GP 20 (80%) 
                         Academic GP 1 (4%) 
                         Other 4 (16%) 
Practice host research  Yes 18 (72%)
                                           No 6 (24%) 
                                           Don’t know 1 (4%) 
Postgraduate degree    Yes 5 (20%) 
                                          No 20 (80%) 
Guideline development involvement      Yes 3 (12%)
                                                                          No 22 (88%) 
 
 
Table 2: Delphi ratings for the recommendations’ applicability to primary care patients, before and after 
reading a summary of relevance of the evidence base to primary care (PC) patients. 
NICE guideline & 
recommendation number 
PC relevant 
/total studies 
(n) 
Mean rating 
before evidence 
(range)* 
Mean rating 
after evidence 
(range)* 
Difference after 
seeing evidence 
(95%CI) 
Low PC relevance of studies1 
CG100/R17(Alcohol & 
thiamine) 
0/2 7.2 (4-9) 5.6 (2-9) -1.6**(1.14-
2.22) 
CG101/U4(Long acting 
muscarinic antagonist in COPD) 
0/1 7.7 (5-9) 6.0 (2-9) -1.7**(1-2.44) 
CG101/U1(Post bronchodilator 
spirometry in COPD) 
0/2 7.5 (5-9) 6.0 (2-9) -1.5** (0.86-
2.18) 
CG108/R27(Offer ACE 
inhibitors & β blockers for 
heart failure) 
0/7 7.8 (3-9) 6.9 (1-9) -0.9** (0.35-
1.49) 
CG116/ R11(Trial elimination of 
the suspected food allergen)   
0/10 6.2 (3-9) 4.6 (2-9) -1.6** (1.08-
2.17) 
CG122/R 1.1.2.1(Serum CA125 
in PC in ovarian cancer) 
0/6 7.9 (5-9) 5.8 (2-9) -2.1** (1.34-
2.90) 
Medium PC relevance of studies2 
CG127/R15(Ambulatory BPM 
to confirm hypertension) 
20/50 7.5 (2-9) 6.5 (2-9) -1.0** (0.24-
1.76) 
CG127/R16(Home BPM to 
confirm hypertension) 
3/8 7.4 (4-9) 6.4 (2-9) -1.0** (0.56-
1.52) 
CG122/R 1.1.1.2(Test women 
with persistent symptoms for 
ovarian cancer) 
9/16 7.7 (5-9) 7.1 (3-9) 0.6** (0.05-1.23)
CG123/R1.3.1.1(Ask people 
who may have depression 2 
questions) 
11/20 6.6 (1-9) 6.6 (1-9) 0 (-0.38-0.46) 
High PC relevance of studies3 
CG108/R3(Measure serum 
natriuretic peptides in heart 
failure) 
2/3 8.2 (6-9) 8.3 (6-9) +0.1 (-0.27-0.27)
CG95/R1.2.1.3(Acute 
coronary syndrome) 
3/4 7.8 (5-9) 7.8 (4-9) 0 (-0.18-0.26) 
CG102/R 1.2.2(Children & 
meningitis without rash & 
antibiotics 
4/5 7.1 (2-9) 7.4 (2-9) +0.3 (-1.02-0.54)
CG101/U2(Consider 
alternative diagnosis if 
FEV1/FVC is <0.7 
4/4 7.2 (4-9) 7.6 (3-9) +0.4 (-1.1-0.28)
*Scores were on a scale from 1-9. ** Statistically significant using paired t-test
1 = completely irrelevant recommendation, not be likely to implement  
9 = trusted recommendation, are likely to use, highly relevant to patients 
1. Low PC relevance of studies= none of the studies cited as evidence for the recommendation had 
population selected from primary care or the community. 
2. Medium PC relevance = Up to half of the studies cited as evidence had their participants selected 
from PC or the community. 
3. High PC relevance = Majority of the studies cited as evidence had their participants selected from 
PC or the community. 
 
Table 3: Scores for attributes affecting guideline use 
Factors related to the guideline topic Mean rating  
(range) 
Primary care setting indicated in guideline title 4.2 (2-5) 
Priority in a primary care setting 4.3 (2-5)
Focus of guideline recommendations on clinical presentation and 
diagnosis 
3.8 (2-5) 
Perceived need for change in clinical practice in a certain area 4.2 (3-5)  
Factors related to guideline characteristics:
Produced by a reputable body or authority 4.5 (3-5)
General practitioners involved in development  of guideline 4.4 (3-5)
An organisation of which I am a member was involved in 
the guideline production 
3.5 (2-5)  
Guidance consistent with other available sources or my previous 
practice 
3.9 (2-5) 
Factors related to the accessibility of the Guideline: 
Easy to access or in a format I recognise so I can find key 
information quickly 
4.7 (4-5) 
Recommendations are written in a clear, logical, and well 
organised manner 
4.7 (4-5) 
Executive summary or clear algorithm showing clinical 
recommendations 
4.6 (4-5) 
Not too long 4.4 (3-5) 
Factors related to the evidence on which the recommendations are based
Study outcomes used are relevant and important to primary care 
population 
4.5 (2-5) 
Evidence underpinning recommendation comes from secondary 
care population 
2.8 (1-5) 
Link from evidence to recommendation is clear and logical and 
easy to find 
4 (2-5) 
Applicability to primary care population e.g. severity of disease 
and comorbidity is taken into consideration and discussed  
4.5 (2-5) 
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Many thanks for agreeing to take part in our 2 stage Delphi panel. We appreciate you completing the questionnaire, which should 
not take more than 15 minutes. The aim of the study is to improve NICE guideline development and the relevance of guideline 
recommendations to managing patients seen in primary care settings. The evidence base used for guidelines is not always 
derived from research in primary care, and the relevance and applicability of recommendations for patients in primary care 
settings has been questioned. This Delphi process is looking into your views on this, using specific guidelines as examples. 
In the first round, we are asking you to rate some NICE guideline recommendations, as well as some factors related to your 
guideline use. After this round we will be collating responses and providing feedback to you and all our panellists, testing 
consensus across the group of panellists. 
Background
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The following section asks some details about you and your current role. Any contact details you provide will be confidential, and 
will only be used by the researcher to feedback results to you. Your individual details or responses will not be identified by any of 
the other panellists 
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Years since qualified as a general practitioner
Split Page Here  
Would you describe your primary role as:
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Do you hold a postgraduate academic degree? i.e. Master, MD, PhD
Split Page Here  
Does the practice where you work regularly host research?
Split Page Here  
*
*
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Male
Female
Prefer not to say
Other (please specify) 
Service GP Academic GP
Other (please specify)
Yes (if yes give details) No
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Have you previously ever been involved in guideline development? 
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In this section we will be asking you to rate a sample of NICE recommendations from various guidelines that have been 
specifically selected by a panel of GPs as relevant to patient groups/ conditions managed in primary care. 
Please rate each recommendation according to the relevance of each recommendation to your practice/ patients. By "relevant" 
we mean how much you would trust the advice or guidance contained in the recommendation to be applicable to your typical 
primary care patient.  
Rate each recommendation on a scale from 1 - 9. A score of 9 would mean a recommendation that you trust, are likely to use, 
and find highly relevant to your patients, while a score of 1 means the recommendation is completely irrelevant and you would not 
be likely to implement it with your patients. You are asked to rate each recommendation twice: first after reading the 
recommendation, and then again after reading a very brief summary of the evidence base for the recommendation.  
At the end of each recommendation there is a link to the full guidance for you to consult if you feel you need to.  
1a) CG 95 (Chest pain of recent onset):  
Recommendation 1.2.1.3:  
“Initially assess people for any of the following symptoms which may indicate an ACS (acute coronary syndrome), 
pain in the chest and/or other areas (for example, the arms, back or jaw) lasting longer than 15 minutes, chest pain 
associated with nausea and vomiting, marked, sweating, breathlessness, or particularly a combination of these, 
chest pain associated with haemodynamic instability, new onset chest pain, or abrupt deterioration in previously 
stable angina, with recurrent chest pain occurring frequently and with little or no exertion, and with episodes often 
lasting longer than 15 minutes.”  
If you require any more infomation, the full guidance can be viewed here
Guideline recommendations rating
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) highly 
relevant
N/A
Show this page only
Yes No
Other (please specify)
Any comments 
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Evidence: Four studies including 3 systematic reviews and one cohort study. Two of the systematic reviews and the cohort study 
used patients from primary care and emergency care 
1b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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2a) CG100 (Alcohol-use disorders- Diagnosis and clinical management of alcohol-related physical complications):  
R17:  
"Offer thiamine to people at high risk of developing, or with suspected, Wernicke’s encephalopathy. Thiamine 
should be given in doses toward the upper end of the ‘British national formulary’ range. It should be given orally or 
parenterally as described in recommendations 1.2.1.2 to 1.2.1.4.”  
If you require more details, the full guidance can be viewed here. 
Recommendation rating (cont.)
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
Any comments 
Any comments 
Q10 Add Question Logic Move Copy Delete  
Q9 Add Question Logic Move Copy Delete  Edit Question ▼
Edit Question ▼
Edit Page Options ▼
Edit Page Options ▼
+ Add Question ▼
+ Add Question ▼
+ Add Question ▼
+ Add Question ▼
Page 4 of 20SurveyMonkey - Question Builder
22/11/2012http://www.surveymonkey.net/MySurvey_EditorFull.aspx?sm=2GUgDb9WZvO5V9...
+ Add Page
PAGE 6  Add Page Logic Move Copy Delete Show this page only
Evidence: Two studies that recruited cases of Wernicke's encephalopathy admitted to hospital for treatment. Neither study 
included patients from primary care setting. 
2b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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3a) CG101 (Chronic obstructive pulmonary disease-Management of chronic obstructive pulmonary disease in 
adults in primary and secondary care):  
U4:  
“Offer once-daily long-acting muscarinic antagonist (LAMA) in preference to four-times-daily short-acting 
muscarinic antagonist (SAMA) to people with stable COPD who remain breathless or have exacerbations despite 
using short-acting bronchodilators as required, and in whom a decision has been made to commence regular 
maintenance bronchodilator therapy with a muscarinic antagonist."  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.)
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
Any comments 
Any comments 
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Evidence: One study of patients over 40 years of age from secondary care centres in the Netherlands and Belgium, which 
excluded patients with asthma, allergic rhinitis,atopy, elevated eosinophils, ,supplemental oxygen, a recent upper respiratory tract 
infection, or a significant disease other than COPD
3b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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4a) CG101 (Chronic obstructive pulmonary disease- Management of chronic obstructive pulmonary disease in 
adults in primary and secondary care): 
U1:  
“Measure post-bronchodilator spirometry to confirm the diagnosis of COPD”.  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.)
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
Any comments 
Any comments 
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Evidence: Two observational studies of patients over 40, one of patients from five Latin American cities and the other of patients 
from UK hospitals  
4b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
PAGE 11  Add Page Logic Move Copy Delete Show this page only
5a) CG101 (Chronic obstructive pulmonary disease- Management of chronic obstructive pulmonary disease in 
adults in primary and secondary care) : 
U2 :  
“Consider alternative diagnoses or investigations in: older people without typical symptoms of COPD where the 
FEV1/FVC ratio is < 0.7, younger people with symptoms of COPD where the FEV1/FVC ratio is ≥ 0.7”.  
If you reqiure more details, the full guidance can be viewed here
Recommendation rating (cont.)
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
Any comment 
Any comment 
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Evidence: Four cross sectional studies, all included patients from community and primary care. 
5b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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6a) CG102 (Bacterial meningitis and meningococcal septicaemia- Management of bacterial meningitis and 
meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care):  
Recommendation 1.2.2:  
“Transfer children and young people with suspected bacterial meningitis without non-blanching rash directly to 
secondary care without giving parenteral antibiotics”.  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.)
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
Any comments 
Any comments 
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Evidence: Five studies, three of which included patients in primary care or pre hospital. One systematic review with two thirds of 
its included studies restricted to primary care patients. 
6b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
*
(1) Not relevant (2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
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7a) CG108 (Chronic heart failure- Management of chronic heart failure in adults in primary and secondary care):  
R3:  
“Measure serum natriuretic peptides (B-type natriuretic peptide [BNP] or N-terminal pro-B-type natriuretic peptide 
[NTproBNP]) in patients with suspected heart failure without previous MI”.  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.):
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
Any comment 
Any comments 
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Evidence: Three systematic reviews, two included many studies from primary care, and one of the two was specifically about 
diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. 
7b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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8a) CG108 (Chronic heart failure- Management of chronic heart failure in adults in primary and secondary care):  
R27:  
“Offer both angiotensin-converting enzyme (ACE) inhibitors and beta-blockers licensed for heart failure to all 
patients with heart failure due to left ventricular systolic dysfunction. Use clinical judgement when deciding which 
drug to start first”.  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.):
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
Any comments 
Any comments 
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Evidence: Seven clinical trials that all recruited patients with moderate to severe heart failure from secondary care. 
8b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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9a) CG116 (Food allergy in children and young people- Diagnosis and assessment of food allergy in children and 
young people in primary care and community settings):  
Recommendation 1.1.11: 
“Based on the results of the allergy-focused clinical history, if non-IgE-mediated food allergy is suspected, trial 
elimination of the suspected allergen (normally for between 2–6 weeks) and reintroduce after the trial. Seek advice 
from a dietician with appropriate competencies, about nutritional adequacies, timings of elimination and 
reintroduction, and follow-up”.  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.):
*
Any comments 
Any comments 
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Evidence: Ten studies and expert consensus, All the studies were low quality, secondary care and non UK. The guideline 
acknowledged that evidence for patch testing was all taken from secondary or specialist settings and may not be directly 
applicable to a diverse primary care population. 
9b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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10a) CG122 (Ovarian cancer- The recognition and initial management of ovarian cancer): 
Recommendations 1.1.2.1:  
“Measure serum CA125 in primary care in women with symptoms that suggest ovarian cancer (see section 1.1.1).”  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.):
*
Any comments 
Any comments 
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Evidence: Six systematic reviews of secondary care studies. There was no direct evidence about the performance of serum 
CA125 test, ultrasound and pelvic examination in primary care. 
10b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base
*
(1) not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) highly 
relevant
N/A
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11a) CG122 (Ovarian cancer- The recognition and initial management of ovarian cancer): 
Recommendation 1.1.1.2: 
“Carry out tests in primary care (see section 1.1.2) if a woman (especially if 50 or over) reports having any of the 
following symptoms on a persistent or frequent basis – particularly more than 12 times per month: • persistent 
abdominal distension (women often refer to this as ‘bloating’) • feeling full (early satiety) and/or loss of appetite • 
pelvic or abdominal pain • increased urinary urgency and/or frequency”  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.):
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
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Evidence: Sixteen studies most were retrospective. Eight of the studies plus a systematic review, included women presenting in 
primary care or population based surveillance studies. The remaining seven studies were secondary care based. 
11b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base:
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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12a) CG123 (Common mental health disorders- Identification and pathways to care): 
Recommendation 1.3.1.1:  
“Be alert to possible depression (particularly in people with a past history of depression, possible somatic 
symptoms of depression or a chronic physical health problem with associated functional impairment) and consider 
asking people who may have depression two questions, specifically: • During the last month, have you often been 
bothered by feeling down, depressed or hopeless? • During the last month, have you often been bothered by having 
little interest or pleasure in doing things? If a person answers ‘yes’ to either of the above questions consider 
depression and follow the recommendations for assessment".  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.)
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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Other (please specify) 
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Evidence: Twenty studies, 11 of which included patients seen in primary care or community clinics. The rest of the studies were 
secondary care based. 
12b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base:
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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13a) CG127 (Hypertension- The clinical management of primary hypertension in adults):  
Recommendation 15:  
“When using ABPM to confirm a diagnosis of hypertension, ensure that at least two measurements per hour are 
taken during the person’s usual waking hours (for example, between 08:00 and 22:00).Use the average value of at 
least 14 measurements taken during the person’s usual waking hours to confirm a diagnosis of hypertension"  
If you require more details, the full guidance here
Recommendation rating (cont.)
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
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Evidence: Over 50 studies, of which 20 recruited patients from primary care or the general population. However, none of the 
primary care studies were UK based. The two UK studies were secondary and tertiary care. 
13b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base: 
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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14a) CG127 (Hypertension- The clinical management of primary hypertension in adults): 
Recommendation 16:  
“When using HBPM to confirm a diagnosis of hypertension, ensure that: for each blood pressure recording, two 
consecutive measurements are taken, at least 1 minute apart and with the person seated and blood pressure is 
recorded twice daily, ideally in the morning and evening and blood pressure recording continues for at least 4 days, 
ideally for 7 days. Discard the measurements taken on the first day and use the average value of all the remaining 
measurements to confirm a diagnosis of hypertension”.  
If you require more details, the full guidance can be viewed here
Recommendation rating (cont.)
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
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Evidence: Eight studies, all non UK. Three of these studies included population based cohorts and the rest were secondary care 
patients.  
14b) Having read a summary of evidence source, can you please re rate the same recommendation?
Evidence base:
*
(1) Not 
relevant
(2) (3) (4) (5) (6) (7) (8) (9) Highly 
relevant
N/A
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In this section we are asking about your use and views of guidelines.  
How often would you ESTIMATE that you refer to NICE guidelines during your clinical practice? 
Section 3: Your general views on guideline use and attributes
*
          
Any comments 
Any comments 
Never
More than once a week
Weekly
Monthly
Less than once a month
Other (please specify)
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Below is a list of guideline attributes identified from the literature that could affect primary care practitioners’ use of guidelines. 
The attributes have be divided into different categories presenting various aspects of the guideline. With a specific focus on NICE 
guidelines, please rate each factor on a scale of 1-5 (5 being you strongly agree that this attribute is mostly likely to encourage 
you to use a clinical guideline and 1 being least likely to encourage you to use a guideline). Each section also allows you to opt 
for ‘don’t know/unsure’. At the end of each section there is a space for you to provide any comments or add any other factors you 
think are relevant. 
Guideline topic:
Split Page Here  
Guideline characteristics:
Guideline attributes
*
Strongly 
agree Agree
Neither 
agree or 
disagree
Disagree Strongly 
disagree
Not sure/ 
don't know
Primary care setting indicated in guideline title
Priority in a primary care setting
Focus of guideline recommendations on clinical presentation and diagnosis
Perceived need for change in clinical practice in a certain area
*
Strongly 
agree Agree
Neither 
agree nor 
disagree
Disagree Strongly 
disagree
Not sure/ 
don't know
Produced by a reputable body or authority
General practitioners involved in development guideline
An organisation of which I am a member was involved in the guideline 
production
Guidance consistent with other available sources or my previous practice
Any comments or other factors 
Any comments or other factors 
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Split Page Here  
Accessibility of the guideline
Split Page Here  
The evidence on which the recommendations are based:
Split Page Here  
Other attributes:  
In the space below please describe any factors that you think are relevant which are not mentioned in the above list. 
*
Strongly 
agree Agree
Neither 
agree nor 
disagree
Disagree Strongly 
disagree
Not sure/ 
don't know
Easy to access orin a format I recognise so I can find key information 
quickly
Recommendations are written in a clear, logical, and well organised 
manner
Executive summary or clear algorithm showing clinical recommendations
Not too long
*
Strongly 
agree Agree
Neither 
agree nor 
disagree
Disagree Strongly 
disagree
Not sure/ 
don't know
Study outcomes used are relevant and important to primary care population
Evidence underpinning recommendation comes from secondary care 
population
Link from evidence to recommendation is clear and logical and easy to find
Applicability to primary care population e.g. severity of disease and co-
morbidity is taken into consideration and discussed
Any comments or other factors 
Any comments or other factors 
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Appendix 2 
 
NICE guidelines- Focus group topic guide 
 
 
Welcome & introduction of researchers  
 
Purpose of focus group 
 
Telling participants the general purpose of the focus group and the time estimate will 
be 1 hour  
Reminding participants that their answers will be used for research remain confidential, 
and that their names will remain anonymous.  
Get them to sign consent form 
 
Starting (warm up) questions 
Do you ever read a guideline? Do you use guidelines? How many times you think you 
referred to guidelines in the last month? 
What do you think of NICE guidelines? 
Can you think of any recent examples where you referred to NICE to guidelines for 
consultation? And how did you find that? 
 
Main discussion topic 
What is you first reaction when you receive a new NICE guideline? 
 
How do you identify recommendations that relevant to you? 
 
What do you consider when you decide to adopt or use a certain guideline or 
recommendation? (Prompts here will be the list of factors identified from the literature 
and rated by the Delphi panel; characteristics, accessibility, evidence base) 
How do you access guidelines and which version do you read (if you do)? do you ever 
check the GP representation on the development group, do you ever read the evidence 
to recommendation section? 
If the evidence for a recommendation for use in primary care comes from studies done 
on secondary care, does this change your mind?  
 
Going back to the earlier examples of good or bad recommendations encountered 
recently, why you think these particular recommendations were good/ bad? 
 
If you were to change something about current guidelines, what would you change? 
What would make NICE guidelines more usable in general practice? 
 
